A supplemental New Drug Application has been submitted to

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

May 7, 2014 at 8:00 AM

A supplemental New Drug Application has been submitted to the U.S. FDA for Simeprevir in combination with Sofosbuvir

· The Supplemental New Drug Application for OLYSIO™ (simeprevir) for once -daily use in combination with sofosbuvir is for 12 Weeks treatment of adult patients with genotype 1 chronic hepatitis C. · The filing includes data from treatment naïve patients with advanced liver fibrosis and prior null responders with all stages of liver fibrosis. Stockholm, Sweden — Medivir AB (OMX: MVIR) today announces that Janssen has submitted a supplemental New Drug Application (sNDA) to the Food and Drug Association (FDA) for simeprevir, an NS3/4A protease inhibitor marketed as OLYSIO™ in the United States, in combination with the nucleotide analogue NS5B polymerase inhibitor sofosbuvir developed by Gilead Sciences, Inc. “It is of great importance to continue to improve the treatments for hepatitis C. The supplemental filing of the data available on the combination of simeprevir and sofosbuvir is an important step towards making an efficacious once daily all-oral treatment available for these patients“, says Charlotte Edenius, EVP Development, Medivir. OLYSIO™ is currently approved in the U.S. for the treatment of chronic hepatitis C infection as a component of a combination antiviral treatment regimen. OLYSIO™ efficacy has been established in combination with peginterferon alfa and ribavirin in HCV genotype 1-infected patients with compensated liver disease, including cirrhosis. This regulatory submission is for the treatment of genotype 1 chronic hepatitis C (HCV) in adult treatment-naïve patients with advanced fibrosis and null responders with all stages of liver fibrosis. The regulatory submission for OLYSIO™ and sofosbuvir is supported by data from the phase II COSMOS study which included treatment-naïve patients with advanced fibrosis (METAVIR F3 to F4 scores) and prior null-responder patients with all stages of liver fibrosis (METAVIR F0 to F4 scores). Our partner, Janssen R&D Ireland Ltd initiated in April 2014 the phase III OPTIMIST (Optimal Treatment with a simeprevir and sofosbuvir Therapy) trials examining the safety and efficacy of simeprevir and sofosbuvir without interferon or ribavirin for the treatment of chronic genotype 1 HCV infection. In the first trial, known as OPTIMIST-1, the combination will be administered once daily for 8 or 12 weeks in chronic HCV genotype 1 infected patients without cirrhosis who are HCV treatment naive or treatment experienced. In the second trial, known as OPTIMIST-2, the combination will be administered once daily for 12 weeks in HCV genotype 1 infected patients with cirrhosis who are HCV treatment naive or treatment experienced. For more information please visit www.clinicaltrials.gov. For more information please contact: Rein Piir, EVP Corporate Affairs & IR, mobile: +46 708 537 292 Medivir is required under the Securities Markets Act to make the information in this press release public. The information was submitted for publication at 13.50 CET on 7 May 2014. About Simeprevir Simeprevir is an NS3/4A protease inhibitor jointly developed by Janssen R&D Ireland and Medivir AB and indicated for the treatment chronic hepatitis C infection in combination with pegylated interferon and ribavirin in HCV genotype 1 and 4 infected patients with compensated liver disease, including cirrhosis. Janssen is responsible for the global clinical development of simeprevir and has exclusive, worldwide marketing rights, except in the Nordic countries. Medivir AB retains marketing rights for simeprevir in these countries under the marketing authorization held by Janssen-Cilag International NV. Simeprevir was approved for the treatment of chronic hepatitis C infection as part of an antiviral treatment regimen in combination with pegylated interferon and ribavirin in genotype 1 infected adults with compensated liver disease, including cirrhosis in September 2013 in Japan, in November 2013 in Canada and the U.S. and in March 2014 in Russia. A Marketing Authorisation Application was submitted to the European Medicines Agency (EMA) in April 2013 by Janssen-Cilag International NV seeking approval of simeprevir for the treatment of genotype 1 or genotype 4 chronic hepatitis C and the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending Marketing Authorisation in the European Union for the use of simeprevir in combination with other medicinal products for the treatment of chronic HCV. This application is under review by the EMA. About Medivir Medivir is an emerging research-based pharmaceutical company focused on infectious diseases. Medivir has world class expertise in polymerase and protease drug targets and drug development which has resulted in a strong infectious disease R&D portfolio. The Company’s key pipeline asset is simeprevir, a novel protease inhibitor for the treatment of hepatitis C that is being developed in collaboration with Janssen R&D Ireland. The company is also working with research and development in other areas, such as bone disorders and neuropathic pain. Medivir has also a broad product portfolio with prescription pharmaceuticals in the Nordics.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Miami Backyard Ultra: Runners Face Ultimate Test

A New Challenge for Miami's Running Scene Mark the date: December 19, 2026. Miami is about to dive headfirst into the madness of the backyard ultra scene. At 8 AM sharp, the inaugural Miami Backyard Ultra kicks off at the Miami Marine Stadium & Basin Trail on Virginia Key, promising a grueling, yet thrilling, test of endurance. It’s like this city’s stepping up with...

Travel Deal Tuesday Offers Major Savings Opportunities

Travel aficionados, pay attention! Hopper's Travel Deal Tuesday is back, and if there's any day to catch a break on your jet-setting costs, it's December 1st. Travel costs have been on a steep incline, with domestic airfares up a whopping 40% over the past year. This year marks the tenth anniversary of Travel Deal Tuesday, and Hopper is pulling out all the stops to save...

Universal Music CFO to Speak at Major Tech Conference

UMG Steps into the Spotlight at Morgan Stanley Event Music, money, and technology—it's a compelling trio. Universal Music Group (EURONEXT: UMG) is sending its heavyweights, Matt Ellis and Michael Nash, to the Morgan Stanley European Technology, Media & Telecom Conference on November 18, 2026. This isn't just any run-of-the-mill industry hobnob. We're talking about the...

Raytron Dominates Global Thermal Imaging Market in 2026

Raytron's Market Supremacy: By the Numbers If you're looking at the thermal imaging sector and wondering what's what, take a clue from Raytron. This outfit isn't just playing the game—it's running the show with a staggering 30% of the global market in 2025. That's right, they hold the medal for leading global shipments in thermal imaging, and unlike many industries...

Premium Guard Inc. Secures 2027 Top Supplier Honor

This ain't your everyday pat on the back—when Premium Guard Inc. (PGI) snagged the 2027 Top Supplier title from MEMA Aftermarket Suppliers and aftermarketNews, it was a nod to their hustle in the wild world of automotive. Yeah, the guys in Memphis are overachievers, consistently nudging the envelope of car parts. Why Premium Guard Stands Out Let’s be real, it’s not...

Jing'an District Drives Bold Investments at 2026 CIIE

Jing'an's Strategic Moves at 2026 CIIE When you hear "Shanghai," you probably think bright lights, bustling streets, and a city that never sleeps. Now narrow that down even further and you get Jing'an District—a place that's climbing the ladder not just in glitz, but in strategic moves that matter. This year, during the China International Import Expo (CIIE), Jing'an...

Gilbert Welcomes Luxury Florals: French Florist Expands

A Fresh Bloom in Gilbert: French Florist Steps In Toss aside your preconceived notions of what a florist shop should be. When French Florist sets up shop, it's not just about selling flowers—they’re a game-changer in the floral industry. As of November 4, they've stamped their luxury mark in Gilbert, Arizona, courtesy of Ronny and Nicole Record, who aren’t your...

Day Out Snacks Brings Back Sold-Out Peppermint Bark

Spicing Up the Holidays with a Best-Seller Return You've got to love when a brand nails it in the holiday treat department, and Day Out Snacks is playing a winning hand by bringing back their Peppermint Bark protein balls. Here we are again, one year after they flew off the shelves like Santa spotted on Christmas Eve. And let me tell you, this re-release has the potential...

COP31 Highlights: Energy Transition's Role in Competition

Energy Transition: The New Competitive Edge Forget everything you thought you knew about energy as just a line item in an industry ledger. At the heart of the ongoing COP31 gathering in Antalya, Türkiye, is the revelation that energy has morphed into something greater—it's become the battleground for global competitive advantage. Ali Y. Koç didn't mince words when he...

Envista's $430M Senior Notes: A Market Move Decoded

Envista on the Move with $430M Notes Ever feel like the market's a bit like a rollercoaster with no brakes? That's kind of where we're at with Envista Holdings Corporation (NYSE: NVST) rolling out this new financial play. They just priced a hefty $430 million in Senior Notes at a solid 6.250% due 2033. In terms of the investment world, that's a pretty big splash. The...